Showing results (351-360 of 359) with videos related to

Sort By:
Pageof 36
You have reached the last page of results.This site can display upto 359 results.
European Heart Journal|December 19, 2022
Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trialYong-Joon Lee, Jae Young Cho, Seng Chan You, et al.
Free Radical Biology & Medicine|September 17, 2016
Ezetimibe, an NPC1L1 inhibitor, is a potent Nrf2 activator that protects mice from diet-induced nonalcoholic steatohepatitisDa Hyun Lee, Dai Hoon Han, Ki Taek Nam, et al.
Nature Communications|May 3, 2020
SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular diseaseSo Ra Kim, Sang-Guk Lee, Soo Hyun Kim, et al.
Diabetologia|February 9, 2023
Tcf7l2 in hepatocytes regulates de novo lipogenesis in diet-induced non-alcoholic fatty liver disease in miceDa Som Lee, Tae Hyeon An, Hyunmi Kim, et al.
Diabetes & Metabolism Journal|November 29, 2024
Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Mellitus: A Review and Position Statement of the Fatty Liver Research Group of the Korean Diabetes AssociationJaehyun Bae, Eugene Han, Hye Won Lee, et al.
Diabetes & Metabolism Journal|June 26, 2019
Efficacy and Safety of Omega-3 Fatty Acids in Patients Treated with Statins for Residual Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled Clinical TrialJi Eun Jun, In Kyung Jeong, Jae Myung Yu, et al.
Endocrinology and Metabolism (Seoul, Korea)|August 22, 2024
Study Design and Protocol for a Randomized Controlled Trial to Assess Long-Term Efficacy and Safety of a Triple Combination of Ezetimibe, Fenofibrate, and Moderate-Intensity Statin in Patients with Type 2 Diabetes and Modifiable Cardiovascular Risk Factors (ENSEMBLE)Nam Hoon Kim, Juneyoung Lee, Suk Chon, et al.
Hepatology International|June 15, 2024
A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver diseaseHuai Zhang, Giovanni Targher, Christopher D Byrne, et al.
Autophagy|February 26, 2021
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1Daniel J Klionsky, Amal Kamal Abdel-Aziz, Sara Abdelfatah, et al.
Pageof 36